The difference between benign prostatic hyperplasia and prostate cancer.

Written by Zhou Zi Hua
Oncology
Updated on September 14, 2024
00:00
00:00

Prostatic hyperplasia and prostate cancer are sometimes very difficult to distinguish clinically, as both diseases occur in elderly men, can cause lower urinary tract symptoms, and lead to elevated PSA levels. However, prostatic hyperplasia generally has a longer medical history, whereas prostate cancer has a shorter history and progresses more quickly. During a digital rectal exam for prostatic hyperplasia, the gland appears enlarged and the surface is smooth. In contrast, during a prostate exam, the gland may show irregular enlargement, a rough surface, and the tumor feels firm. When these two are difficult to distinguish, considering a prostate biopsy may be advisable.

Other Voices

doctor image
home-news-image
Written by Liu Liang
Oncology
43sec home-news-image

Is prostate cancer prone to metastasis?

Prostate cancer most commonly metastasizes to bones, with multiple bone metastases frequently observed clinically. In fact, the majority of prostate cancer patients already have multiple bone metastases by the time they are diagnosed. Therefore, bone is the most common distant organ to which prostate cancer spreads. Other distant organ metastases, such as to the lungs and liver, are less common, unless in very advanced stages of the disease. Additionally, prostate cancer commonly invades locally, spreading to nearby pelvic structures and tissues, such as the bladder and rectum, which is a common form of local invasion and spread.

doctor image
home-news-image
Written by Liu Liang
Oncology
45sec home-news-image

Can prostate cancer be detected by ultrasound B?

Prostate cancer can generally be detected through ultrasound, as it reveals nodules in the prostate. By examining the internal echoes of these nodules, one can differentiate between benign and malignant prostate conditions. Thus, in foreign countries, ultrasound, specifically prostate color Doppler ultrasound examinations, are used as a screening method for prostate cancer. In China, screening methods also include traditional digital rectal examinations and generally involve blood tests for specific prostate tumor markers, namely PSA. These tests are combined with prostate ultrasound for a comprehensive assessment.

doctor image
home-news-image
Written by Liu Liang
Oncology
56sec home-news-image

What indicators are checked for prostate cancer?

Prostate-Specific Antigen (PSA) is a glycoprotein produced by the vesicles in the cytoplasm of normal or pre-cancerous epithelial cells of the prostate. It is the most specific and sensitive tumor marker for prostate cancer. Therefore, in patients with prostate cancer, we generally conduct blood tests for PSA, especially in screening for prostate cancer, assessing the effectiveness of treatments, and for the prognosis of prostate patients, among other aspects. Additionally, other examinations are combined, such as digital rectal exams, which can also serve as a screening method for prostate cancer. Moreover, CT or MRI scans of the prostate and pelvis, as well as ultrasound examinations of the prostate, can be used in conjunction with the tumor marker PSA for a comprehensive evaluation.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
36sec home-news-image

What are the causes of prostate cancer?

At present, there are many factors that cause prostate cancer, but its exact etiology remains unclear. It may be related to genetic factors, gene changes, prostate gonococcal and chlamydial infections, intensity of sexual activity, and the influence of hormones. Additionally, dietary habits, long-term consumption of high-fat foods, and occupational hazards, such as excessive exposure to chromium, may also be related to the development of the disease.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
1min home-news-image

Pathological classification of prostate cancer

The classification of precancerous lesions of prostate cancer is divided into two categories: intraductal carcinoma of the prostate and atypical adenomatous hyperplasia. Among these, the relationship between intraductal carcinoma of the prostate and prostate cancer is the closest. Intraductal carcinoma of the prostate is currently recognized as a precancerous lesion of prostate cancer, while atypical adenomatous hyperplasia has not been proven to be a precancerous lesion of prostate cancer according to current evidence. However, the biological behavior of this atypical adenomatous hyperplasia is not very clear yet, so it should be closely monitored. The histological classification of prostate cancer mainly includes the majority of acinar adenocarcinoma and a small amount of ductal adenocarcinoma, with acinar adenocarcinoma being a highly invasive malignant tumor.